// App-Quantinova.ai

7502 : Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).

Researchers

Presenter

  • William G. Wierda

Principal Investigators

  • Tanya Siddiqi

  • Ian Flinn

  • Xavier C. Badoux

  • Thomas J. Kipps

  • John N. Allan

  • Alessandra Tedeschi

  • John M. Pagel

  • Bryone J. Kuss

  • Eva Gonzalez Barca

  • Paolo Ghia

  • Karl Eckert

  • Cathy Zhou

  • Joi Ninomoto

  • James P. Dean

  • Danelle Frances James

  • Constantine Tam

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • City of Hope National Medical Center, Duarte, CA

  • Sarah Cannon Research Institute, Nashville, TN

  • St George Hospital, Sydney, Australia

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Swedish Cancer Institute, Seattle, WA

  • Flinders Medical Centre, Bedford Park, Australia

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Universita Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, Australia

Locations

  • United States

  • Spain

  • Italy

  • Australia

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02910583

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved